Zhiyi Biotech is a Guangzhou-based biopharmaceutical R&D firm focused on next-generation probiotics (NGPs) and live biotherapeutics (LBPs) alongside associated therapeutic approaches. The company develops new-drug candidates and therapeutic modalities built on its NGP/LBP platforms. It recently completed the first tranche of a C round financing, raising nearly ¥100 million RMB. Proceeds from the tranche are designated primarily for clinical development across its pipeline. In particular, the company intends to use the funds to advance its candidate SK08 into a Phase III clinical trial. The article does not provide operating metrics, past funding history, or founding year. Zhiyi Biotech is a clinical-stage LBP developer that has built a technical and industrial platform spanning strain isolation, identification, innovative LBP development, CMC and commercial production. Its lead candidate, SK08, is based on a single bacterial strain, Bacteroides fragilis, and is ahead of other LBPs in China. SK08 is expected to complete a Phase II trial in China this year for IBS-D and has an ongoing Phase Ib/II study in combination with a PD-1 inhibitor for advanced solid tumors. The company reports multiple programs preparing IND filings to both the FDA and China’s NMPA, and expects additional programs to enter the clinic over the next year. Zhiyi operates two commercial-scale facilities and says the funds raised will be used to accelerate clinical development of its LBP product lines.

Total raised

$29M

Funding rounds

2

Latest round

Series C

Latest activity

Mar 2024